Activity of Nivolumab and Ipilimumab Combination in the Treatment of Metastatic Uveal Melanoma
Results of phase II study with combination of two immune checkpoint inhibitors in rare subtype of melanoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC
FDA also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic
FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers and Biomarkers
Indications concern identification of BRCA1 and/or BRCA2 mutations in ovarian cancer, PIK3CA mutations in breast cancer, ALK rearrangements in NSCLC, BRCA1, BRCA2, and/or ATM mutations in mCRPC
Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Results of the first phase III study to evaluate the use of the UGT1A1 genotype for guiding the irinotecan dose in this setting
Identification of Actionable Molecular Alterations in NCI-MATCH
Feasibility of complex, genomically guided clinical trial in oncology
Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination Therapy in the S1320 Study
Intermittent treatment does not improve progression-free survival in BRAF-mutated melanoma
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours for Larotrectinib
NGS-based test identifies fusions in NTRK genes in DNA isolated from tumour tissue specimens
Feasibility and Preliminary Efficacy Results of the Beat AML Study
Data from the prospective genomic profiling
ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage II Colon Cancer
3-year disease-free survival rate comparable with 3- vs 6-month treatment
FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukaemia
Efficacy was confirmed in VIALE-A and VIALE-C studies
EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan
Lenalidomide Mylan is a generic of Revlimid, which has been authorised in the EU since 2007
EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells
Intended use is for the treatment of relapsed or refractory mantle cell lymphoma